Drug Profile
AVN 322
Alternative Names: AVN-322Latest Information Update: 12 Sep 2021
Price :
$50
*
At a glance
- Originator ChemDiv
- Developer AllaChem; Avineuro Pharmaceuticals
- Class Nootropics; Pyrimidines; Small molecules
- Mechanism of Action Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 08 Sep 2021 Phase II development in Alzheimer's disease is ongoing in USA (Avineuro Pharmaceuticals pipeline, September 2021)
- 12 Sep 2016 Phase-II clinical trials in Alzheimer's disease in USA before September 2016 (Spring Bank Pharmaceuticals pipeline, September 2016)
- 13 Nov 2013 Phase-I development is ongoing in USA